Financial Performance - In 2021, the company's operating revenue reached CNY 796,657,258, representing a 58.70% increase compared to CNY 501,981,691 in 2020[22]. - The net profit attributable to shareholders of the listed company was CNY 106,603,635, a 100.95% increase from CNY 53,050,474 in the previous year[22]. - The basic earnings per share for 2021 was CNY 0.71, up 102.86% from CNY 0.35 in 2020[23]. - The total assets of the company increased by 48.01% to CNY 1,960,497,669.74 at the end of 2021, compared to CNY 1,324,609,139.70 at the end of 2020[22]. - The company's net assets attributable to shareholders increased by 12.07% to CNY 1,165,968,552 at the end of 2021[22]. - The net profit after deducting non-recurring gains and losses was CNY 92,449,315.57, a 96.11% increase from CNY 47,140,758.18 in 2020[22]. - The company achieved a revenue of 796.66 million RMB in 2021, representing a 58.70% increase compared to the previous year[31]. - The company reported a 50.11% increase in operating costs, primarily due to the corresponding rise in revenue[41]. - The company achieved a main business revenue of 793.62 million yuan in 2021, an increase of 58.60% compared to the previous year[43]. - The operating cost for the same period was 591.69 million yuan, reflecting a 50.04% increase year-over-year[43]. Cash Flow and Investments - The net cash flow from operating activities was CNY 104,966,819.34, a decrease of 13.82% from CNY 121,794,840.68 in 2020[22]. - The net cash flow from operating activities for the first quarter was 16.71 million RMB, while the fourth quarter saw a decrease to 8.78 million RMB[26]. - The company’s investment activities generated a net cash flow increase due to the utilization of idle funds for investments[43]. - The company received funds from issuing convertible bonds, contributing to the net cash flow from financing activities[43]. Production and Market Expansion - The company successfully issued 4.05 million convertible bonds, raising a total of 405 million RMB for projects related to borosilicate glass production and compatibility research[31]. - The production capacity of borosilicate products significantly increased, with the first borosilicate furnace reaching production efficiency and a second furnace project initiated[31]. - The company is advancing its international strategy by building multiple overseas sales platforms and expanding its international market presence[31]. - The company expanded its high-end pharmaceutical packaging market by establishing strategic partnerships with several well-known pharmaceutical companies[31]. - The revenue from the North China region increased significantly by 422.23% year-over-year, indicating strong market performance[46]. Research and Development - The company has a total of 31 patented technologies, including 2 invention patents, enhancing its research and development capabilities[38]. - The company has increased its research and development expenses to 12.08 million RMB, a rise of 46.34% compared to the previous year, indicating a focus on innovation[41]. - The company is focusing on digital transformation in its workshops to enhance production management and efficiency[31]. - The company is committed to continuous improvement in organizational mechanisms and employee capability enhancement[31]. Risks and Challenges - The company has outlined potential risks in its future development strategy, which investors should consider[8]. - The company recognizes the risk of dependency on the pharmaceutical industry, which could impact its performance if the industry experiences a downturn[73]. - The company is aware of potential risks related to product quality issues from downstream clients, which could adversely affect its sales[74]. - The company is facing significant price competition in the bulk procurement segment, leading to a substantial decrease in winning bid prices, which will increase supply chain and quality risks[68]. - The company anticipates a trend of stronger players dominating the market, as larger firms with better financing and technology capabilities will increasingly partner with pharmaceutical companies[68]. Corporate Governance - The company held one shareholders' meeting during the reporting period, ensuring compliance with legal regulations and protecting minority shareholders' rights[79]. - The board of directors convened eight meetings, adhering to relevant laws and regulations to ensure sound decision-making and protect shareholder interests[79]. - The supervisory board held seven meetings, fully complying with legal requirements to oversee the company's operations[79]. - The company maintains transparent performance evaluation and incentive mechanisms for its directors and managers, linking compensation to industry standards and company performance[80]. - The company actively communicates with minority shareholders to keep them informed about significant developments and gather feedback for board consideration[81]. Environmental Responsibility - The company has established a comprehensive environmental protection system and internal control framework, effectively reducing environmental risks[114]. - Key pollutants such as Chemical Oxygen Demand (COD) and Ammonia Nitrogen were reported at 86 mg/L and 2.28 mg/L respectively, both within the emission standards[115]. - The company constructed a wastewater treatment station and has operational facilities for dust removal and denitrification, achieving compliant pollutant discharge[116]. - The company implemented a full oxygen kiln technology transformation, expected to reduce energy consumption and carbon emissions[122]. - No administrative penalties were reported during the reporting period due to environmental issues[121]. Shareholder Information - The total number of shares held by directors and senior management at the end of the reporting period is 40,198,294 shares, unchanged from the beginning of the year[84]. - The total pre-tax remuneration for directors and senior management during the reporting period amounts to 503.45 million yuan[84]. - The company has a diverse board with a mix of male and female directors, including 3 independent directors[84]. - The company’s chairman, Deng Yong, holds 29,305,364 shares, representing a significant stake[84]. - The actual controllers of the company, including Mr. Deng Yong, Ms. Jiang Hui, and Mr. Deng Qiuhan, have pledged not to interfere in the company's management or infringe on its interests[132].

2022 年第一季度报告 证券代码：603976 证券简称：正川股份 重庆正川医药包装材料股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 1 / 12 2022 年第一季度报告 | | 本报告期末 | 上年度末 | 本报告期末比上年度 | | --- | --- | --- | --- | | | | | 末增减变动幅度(%) | | 总资产 | 1,982,528,938.53 | 1,960,497,669.74 | 1.12 | | 归属于上市公司股东的 | 1,192,245,751.73 | 1,165,968,552.00 | 2.25 | ...

Financial Performance - In 2021, the company's operating revenue reached CNY 796,657,258, representing a 58.70% increase compared to CNY 501,981,691 in 2020[22]. - The net profit attributable to shareholders of the listed company was CNY 106,603,635, a 100.95% increase from CNY 53,050,474 in the previous year[22]. - The basic earnings per share for 2021 was CNY 0.71, up 102.86% from CNY 0.35 in 2020[23]. - The total assets of the company increased by 48.01% to CNY 1,960,497,669.74 at the end of 2021, compared to CNY 1,324,609,139.70 at the end of 2020[22]. - The net cash flow from operating activities was CNY 104,966,819.34, a decrease of 13.82% from CNY 121,794,840.68 in 2020[22]. - The company's net assets attributable to shareholders increased by 12.07% to CNY 1,165,968,552 at the end of 2021[22]. - The company reported a weighted average return on equity of 9.66%, an increase of 4.53 percentage points from 5.13% in 2020[23]. - The company's total revenue for Q4 2021 reached ¥244,972,483.27, showing a significant increase compared to previous quarters[25]. - The net profit attributable to shareholders for Q4 2021 was ¥37,801,625.73, marking a substantial rise from earlier quarters[25]. Investment and Growth Strategies - The company plans to distribute a cash dividend of CNY 3.08 per 10 shares, totaling CNY 46,570,044.14, subject to shareholder approval[6]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]. - The company successfully issued 4.05 million convertible bonds, raising a total of 405 million yuan for projects aimed at enhancing production and research capabilities[32]. - The company has established multiple overseas sales platforms, making progress in international market expansion[32]. - The company has deepened strategic partnerships with well-known pharmaceutical companies, expanding its customer base in the high-end product segment[32]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[88]. - The company is focused on building long-term partnerships with large pharmaceutical manufacturers to ensure quality and cost-effective packaging solutions[69]. Research and Development - Research and development expenses rose to 12.08 million RMB, a 46.34% increase compared to the previous year[42]. - The company holds 31 patents, including 2 invention patents, reflecting its strong R&D capabilities[39]. - The company is investing $50 million in R&D for new technologies aimed at enhancing product efficiency[88]. Market and Sales Performance - The revenue from borosilicate glass tube bottles increased by 119.50% year-on-year, indicating strong market demand[46]. - The company's main business revenue from direct sales was CNY 793,164,659.67, with a gross margin of 25.44%, an increase of 4.28 percentage points from the previous year[47]. - The sales network has expanded to over 600 domestic clients, including major pharmaceutical manufacturers[38]. - Market expansion efforts have led to a 25% increase in sales in the Asia-Pacific region[88]. Operational Efficiency - The company has implemented 100% automation in bottle production, significantly enhancing product quality and precision[38]. - The company has accelerated the upgrade of its product structure, focusing on high-end pharmaceutical packaging materials[32]. - The company has integrated production processes from "tube drawing to bottle making," ensuring quality control and meeting customer demands effectively[35]. - The company has reduced operational costs by 5%, improving overall profit margins[88]. Risks and Challenges - The company has outlined potential risks in its future development plans, which investors should consider[8]. - The company faces potential risks from increasing regulatory standards for pharmaceutical packaging materials, which may require continuous upgrades in production processes and technology[74]. - The company is vulnerable to fluctuations in the pharmaceutical industry's growth and demand for packaging materials[74]. - The company faces risks related to the quality issues of downstream pharmaceutical clients, which could adversely affect sales and operational performance[75]. - There is a risk that fundraising investment projects may not achieve expected returns due to market changes or policy shifts, impacting the company's profitability[77]. Corporate Governance - The company held one shareholders' meeting during the reporting period, ensuring compliance with legal regulations and protecting minority shareholders' rights[80]. - The board of directors held eight meetings, adhering to regulations and maintaining transparency in decision-making processes[80]. - The company actively communicates with minority shareholders to keep them informed about significant developments and respects their interests[82]. - The company has independent directors who collectively earned 17.85 million yuan in pre-tax remuneration[85]. - The company has a diverse board with a mix of genders, including 3 female directors and 10 male directors[85]. Environmental Responsibility - The company has established a comprehensive environmental protection system and internal control framework, effectively reducing environmental risks[115]. - The company has constructed a wastewater treatment station and operates dust removal and denitrification facilities, achieving compliant pollutant discharge[117]. - The company is currently undertaking multiple environmental impact assessments for ongoing projects, including the production of borosilicate medicinal glass[119]. - The implementation of the 5 all-oxygen kiln technology renovation is expected to reduce energy consumption and carbon emissions[122]. Financial Position - The company's total equity attributable to shareholders reached CNY 1,165,968,552.00, up from CNY 1,040,404,262.01 in the previous year, indicating an increase of about 12%[198]. - The company's debt-to-asset ratio increased significantly to 40.53% from 21.46%, reflecting an 88.86% change[161]. - The total liabilities were reported at RMB 794,529,117.74, significantly higher than RMB 284,204,877.69 in 2020, marking an increase of around 179%[197].

证券代码：603976 证券简称：正川股份 公告编号：2021-063 转债代码：113624 转债简称：正川转债 重庆正川医药包装材料股份有限公司 关于参加重庆辖区 2021 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为推动重庆辖区上市公司进一步做好投资者关系管理工作，提高上市公司规 范运作水平，重庆证监局与重庆上市公司协会、上证所信息网络有限公司联合举 办"重庆辖区 2021 年投资者网上集体接待日活动"。 活动于 2021 年 11 月 25 日下午 15:00-17:00 举行，平台登陆地址为： http://roadshow.sseinfo.com/。 届时，公司高管人员将参加本次活动，通过网络在线交流形式，就公司治理、 发展战略、经营状况、可持续发展等投资者所关心的问题，与投资者进行"一对 多"形式的沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 重庆正川医药包装材料股份有限公司董事会 2021 年 11 月 20 日 1 ...

Financial Performance - The company's operating revenue for the first half of 2021 was approximately ¥324.05 million, representing a 26.57% increase compared to ¥256.02 million in the same period last year[21]. - The net profit attributable to shareholders for the first half of 2021 was approximately ¥38.75 million, an increase of 10.98% from ¥34.92 million in the previous year[21]. - Basic earnings per share for the first half of 2021 were ¥0.26, up 13.04% from ¥0.23 in the same period last year[20]. - The net profit after deducting non-recurring gains and losses for the first half of 2021 was approximately ¥32.79 million, a 7.59% increase from ¥30.48 million in the previous year[21]. - The company achieved operating revenue of CNY 324.05 million, a year-on-year increase of 26.57%[33]. - The net profit attributable to shareholders was CNY 38.75 million, reflecting a growth of 10.98% compared to the previous year[33]. - The company reported a total comprehensive income of RMB 25,412,343.06 for the first half of 2021, down from RMB 28,722,515.80 in the same period last year[115]. Assets and Liabilities - The company's total assets increased by 39.50% to approximately ¥1.85 billion from ¥1.32 billion at the end of the previous year[21]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥1.10 billion, reflecting a 5.89% increase from ¥1.04 billion at the end of the previous year[21]. - As of June 30, 2021, the total assets of the company amounted to RMB 1,847.89 million, with total liabilities of RMB 745.87 million, resulting in a debt-to-asset ratio of 40.36%[99]. - Total liabilities amounted to RMB 746,205,664.73, compared to RMB 284,204,877.69 at the end of 2020, reflecting an increase of around 163.5%[104]. - The company’s cash and cash equivalents rose by 152.05% to CNY 678.73 million, primarily due to funds raised from the convertible bond issuance[36]. Cash Flow - The net cash flow from operating activities for the first half of 2021 was approximately ¥82.82 million, a slight increase of 1.26% from ¥81.79 million in the previous year[21]. - Cash flow from operating activities was CNY 82.82 million, a slight increase of 1.26% from the previous year[33]. - The total cash balance of RMB 678,731,847.13 at the end of the period indicates strong liquidity[199]. Research and Development - Research and development expenses increased by 51.01% to CNY 5.75 million, driven by the addition of new R&D projects[33]. - Research and development expenses for the first half of 2021 were ¥5,747,119.42, up from ¥3,805,855.76 in the same period of 2020[110]. Market Position and Operations - The company is a leading player in the pharmaceutical packaging materials industry, specializing in the production of medicinal glass containers, with over 30 years of development[26]. - The company has established four major production bases and operates thirteen furnaces, making it one of the largest producers of medicinal glass containers in the industry[28]. - The company has a comprehensive production integration of "pulling tube - bottle making - cap production," ensuring product quality and meeting the personalized needs of pharmaceutical enterprises[27]. - The company has established a sales and service network covering over 30 provinces and cities in China, gaining the trust of more than 600 domestic clients[29]. - The company is actively pursuing market expansion and product upgrades to meet the increasing quality demands in the pharmaceutical packaging sector[27]. Environmental Compliance - The company is classified as a key pollutant discharge unit and has maintained compliance with environmental standards during the reporting period[51]. - The company reported a chemical oxygen demand (COD) level of 56 mg/L, significantly below the standard limit of 100 mg/L[52]. - The company has constructed a comprehensive wastewater treatment station and operates dust removal and denitrification facilities, achieving compliant pollutant discharge[53]. - The company has received environmental protection approval for multiple construction projects, with ongoing projects including the medium borosilicate medicinal glass production project[54]. Risks and Challenges - The company faces potential policy risks as national standards for pharmaceutical packaging materials may be raised to align with those in developed countries, impacting production processes and costs[41]. - The company is dependent on the pharmaceutical industry, and any downturn in this sector could directly affect demand for its packaging materials, posing a market risk[42]. - The company’s main products are pharmaceutical glass packaging materials, which may face substitution risks from new materials developed in the industry[43]. - There is a risk that fundraising projects may not yield expected returns due to market changes or policy shifts, affecting the company's profitability[44]. Corporate Governance - The actual controllers of the company committed to not interfering in the company's management activities and not infringing on the company's interests[67]. - The company has committed to avoid any competition with its controlling shareholders and actual controllers[70]. - The company has not reported any new product launches or technological advancements in this period[127]. - The company has committed to improving its compliance and information disclosure practices following the recent incident[75]. Shareholder Information - The total amount of guarantees provided by the company, excluding those to subsidiaries, was 30,000,000 RMB, which represents 2.72% of the company's net assets[80]. - The largest shareholder, Chongqing Zhengchuan Investment Management Co., Ltd., held 39.07% of the shares, totaling 59,077,736 shares[85]. - The company had a total of 37,321 common shareholders at the end of the reporting period[84]. Financial Reporting and Accounting - The financial statements are prepared based on the assumption of going concern, with no significant doubts about the company's ability to continue operations[138]. - The company adheres to the accounting standards, ensuring that the financial statements reflect a true and complete picture of its financial status[139]. - Revenue is recognized based on the progress of performance obligations, with specific criteria for recognizing revenue at a point in time or over time[185].

Financial Performance - Operating revenue for the period was ¥155,709,667.23, representing a growth of 7.65% year-on-year[7] - Net profit attributable to shareholders was ¥19,812,127.11, an increase of 4.34% compared to the same period last year[7] - The basic and diluted earnings per share remained stable at ¥0.13[7] - Total revenue for Q1 2021 reached ¥155,709,667.23, an increase of 7.4% compared to ¥144,647,014.18 in Q1 2020[29] - Net profit for Q1 2021 was ¥19,812,127.11, compared to ¥18,987,705.10 in Q1 2020, representing a growth of 4.3%[30] - The total comprehensive income for Q1 2021 was CNY 19,812,127.11, compared to CNY 18,987,705.10 in Q1 2020, reflecting an increase of approximately 4.35%[31] - Operating revenue for Q1 2021 reached CNY 140,939,138.70, up from CNY 132,694,164.86 in Q1 2020, representing a growth of about 6.88%[31] Assets and Liabilities - Total assets at the end of the reporting period reached ¥1,328,573,399.05, a slight increase of 0.30% compared to the previous year[7] - The total assets of the company increased slightly to ¥1,328,573,399.05 from ¥1,324,609,139.70, reflecting stable growth[21] - The company's total assets as of March 31, 2021, amounted to ¥1,160,071,759.43, slightly up from ¥1,159,884,219.63 at the end of 2020[27] - Current assets totaled ¥667,278,299.59, a marginal increase from ¥663,214,099.02 at the end of 2020[26] - Total liabilities decreased to ¥161,394,284.12 from ¥169,541,827.15, indicating a reduction of approximately 4.3%[27] Cash Flow - Net cash flow from operating activities decreased significantly by 62.83% to ¥16,714,871.20[7] - Operating cash flow decreased significantly by 62.83% to ¥16,714,871.20 from ¥44,973,476.68 year-on-year, primarily due to increased payments for employee salaries and raw material shortages[17] - Cash flow from operating activities generated a net amount of CNY 16,714,871.20 in Q1 2021, down from CNY 44,973,476.68 in Q1 2020, showing a significant decrease of about 62.85%[34] - The company reported a net cash outflow from investing activities of CNY 13,158,150.91 in Q1 2021, compared to CNY 9,764,899.19 in Q1 2020, representing an increase in cash outflow of approximately 34.66%[34] - The net cash flow from financing activities was -16,153,213.91, reflecting substantial cash outflows for debt repayment and dividend distribution[37] - The net increase in cash and cash equivalents was -17,583,782.96, showing a decrease in liquidity during the quarter[37] Shareholder Information - The number of shareholders at the end of the reporting period was 42,728[12] Expenses - Research and development expenses rose by 51.35% to ¥2,118,692.29 from ¥1,399,901.42 in the same period last year, indicating a strong commitment to innovation[16] - Sales expenses increased by 37.09% to ¥8,300,372.69 from ¥6,054,699.64, driven by higher transportation costs due to increased shipping volumes[16] - Research and development expenses for Q1 2021 were ¥2,118,692.29, compared to ¥1,399,901.42 in Q1 2020, marking a significant increase of 51.4%[29] Other Income and Adjustments - The company reported a non-operating income of ¥2,970,646.28 after tax adjustments[10] - The company reported a significant increase in other income, which surged by 2133.69% to ¥3,028,888.55 from ¥135,600.48, mainly due to compensation received[16]

Financial Performance - The company's net profit attributable to shareholders for 2020 was CNY 53,050,474.32, a decrease of 13.11% compared to CNY 61,056,666.09 in 2019[5]. - Operating revenue for 2020 was CNY 501,981,691.39, down 3.67% from CNY 521,080,827.35 in 2019[20]. - The basic earnings per share for 2020 was CNY 0.35, a decline of 12.50% from CNY 0.40 in 2019[22]. - The weighted average return on equity for 2020 was 5.13%, down from 6.04% in 2019[22]. - The total non-recurring gains and losses for 2020 amounted to RMB 5.91 million, with a significant portion attributed to government subsidies[28]. - The company reported a profit margin of 10.6% in 2020, compared to 11.7% in 2019[172]. - The company reported a net profit of ¥285,643,542.27 in 2020, compared to ¥285,770,767.01 in 2019, showing a marginal decrease of approximately 0.04%[165]. Cash Flow and Assets - The net cash flow from operating activities increased significantly by 120.35% to CNY 121,794,840.68 in 2020, compared to CNY 55,273,077.79 in 2019[20]. - The company's total assets attributable to shareholders at the end of 2020 were CNY 1,040,404,262.01, a slight increase of 0.43% from CNY 1,035,979,939.63 at the end of 2019[20]. - Cash and cash equivalents decreased to ¥253,382,202.29 in 2020 from ¥300,349,669.76 in 2019, a decline of approximately 15.6%[167]. - The total current assets of the company were RMB 663.46 million, a decrease from RMB 756.62 million in the previous year, indicating a decline of approximately 12.3%[163]. - The company’s total liabilities increased by 38.66% to ¥284,204,877.69, reflecting a growing debt burden[59]. Production and Operations - The company specializes in the research, production, and sales of pharmaceutical glass packaging materials, including borosilicate glass vials and sodium-calcium glass vials, serving the pharmaceutical industry[30]. - The company operates four major production bases and has 13 furnaces, making it one of the largest producers in the pharmaceutical glass bottle segment[35]. - The company has implemented a fully automated production process, achieving 100% automation in bottle production, significantly improving product quality[37]. - The company has adopted a production model of "order-based production + limited stock," ensuring timely delivery and customization for clients[33]. - The production of borosilicate glass bottles was 242,065 thousand units, with sales volume decreasing by 7.19% to 233,960 thousand units[49]. Research and Development - Research and development expenses increased by 56.52% to CNY 8,253 million, reflecting a focus on innovation[44]. - The company has a total of 28 patented technologies, including 2 invention patents, enhancing its R&D capabilities[38]. - The company is investing $50 million in R&D for new technologies aimed at enhancing product efficiency[131]. Market and Sales Strategy - The company expanded its high-end pharmaceutical packaging market, establishing long-term partnerships with over 170 new clients in 2020[40]. - The company has adopted a customized sales model to participate in pharmaceutical trials and submissions, targeting the mid-to-high-end product market[30]. - The company is focusing on expanding its product offerings in the cosmetics market, contributing to revenue growth in other product categories[48]. - The company is exploring potential acquisitions to enhance its market position, with a budget of $100 million allocated for this purpose[131]. Risk Management - The company has outlined potential risks in its future development strategies, which are detailed in the report[7]. - The company faces potential risks from policy changes that may raise packaging material standards, requiring continuous upgrades in production processes and technology[72]. - The company faces risks related to the quality issues of downstream pharmaceutical clients, which could adversely affect sales and operational performance[73]. Shareholder and Dividend Policy - The company plans to distribute a cash dividend of CNY 0.36 per share, totaling CNY 5,443,200.00, based on a share capital of 151,200,000 shares[5]. - The cash dividends as a percentage of net profit were 10.26% for 2020, 80.23% for 2019, and 14.61% for 2018[84]. - The company has committed to strict adherence to its profit distribution policy to protect minority shareholders' rights[82]. Corporate Governance - The company conducted 2 shareholder meetings during the reporting period, ensuring compliance with relevant regulations[140]. - The board of directors held 8 meetings, adhering to legal and regulatory requirements for governance[140]. - The supervisory board convened 6 meetings, maintaining oversight of the company's legal and compliant operations[140]. - The company actively engages with minority shareholders to ensure transparency and address their concerns[141]. Compliance and Regulatory Matters - The company has taken corrective measures in response to regulatory scrutiny from the China Securities Regulatory Commission, focusing on improving information disclosure and financial accounting practices[105]. - There are no reported penalties from securities regulatory agencies in the past three years, reflecting a stable compliance record[134]. - The company has not encountered any situations that would lead to suspension or termination of its listing[104].

证券代码：603976 证券简称：正川股份 公告编号：2020-067 重庆正川医药包装材料股份有限公司 关于参加重庆辖区 2020 年投资者网上集体 接待日活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为推动重庆辖区上市公司做好投资者关系管理工作，促进上市公司完善公司 治理，进一度提高上市公司质量，重庆证监局与重庆上市公司协会、上证所信息 网络有限公司联合举办"重庆辖区 2020 年投资者网上集体接待日活动"。 活动于 2020 年 11 月 26 日下午 15:00-16:30 举行，平台登陆地址为： http://roadshow.sseinfo.com/。 届时，公司高管人员将参加本次活动，通过网络在线交流形式，就公司治理、 发展战略、经营状况、可持续发展等投资者所关心的问题，与投资者进行"一对 多"形式的沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 重庆正川医药包装材料股份有限公司董事会 2020 年 11 月 20 日 1 ...

2020 年第三季度报告 公司代码：603976 公司简称：正川股份 重庆正川医药包装材料股份有限公司 2020 年第三季度报告 1 / 27 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 2020 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人邓勇、主管会计工作负责人邓勇及会计机构负责人（会计主管人员）肖汉容保证 季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 27 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 1,258,270,989.53 1,240,950,080.73 1.40 归属于上市公司 股东的净资产 ...